awards grant
- 2024 Robert A. Winn Diversity In Clinical Trials: Career Development Award Agreement
- EndoMAP: A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy with Atezolizumab forPatients with Recurrent or Persistent Endometrial Cancer
- Randomized multicenter phase II trial of neoadjuvant chemotherapy plus cemiplimab vs SBRT 8Gy x 3 plus cemiplimab for c-stage IB-IIIA/IIIB (resectable) NSCLC (2024 Winn CDA)